Eli Lilly and Company (NYSE:LLY) Trading Down 1.9% - Here's What Happened

Key Points

• Shares fell 1.9% to about $898.68 on Thursday (intraday low $896.29) with mid‑day volume down ~32% versus the 3.18M average session volume.
• Eli Lilly reported strong Q4 results—EPS $7.54 (vs. $7.48 est.) and revenue $19.29B (+42.6% YoY)—and reiterated FY2026 EPS guidance of 33.50–35.00, driven by GLP‑1 demand and retail expansion for Zepbound.
• Analyst sentiment is mixed: the consensus is a Moderate Buy with an average target of $1,221.44, but HSBC’s downgrade to "reduce" (PT $850), valuation debate versus peers, planned European insulin phase‑outs and GLP‑1 regulatory/public scrutiny add near‑term risks.

Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) fell 1.9% during trading on Thursday . The company traded as low as $896.29 and last traded at $898.6840. 2,154,832 shares were traded during mid-day trading, a decline of 32% from the average session volume of 3,179,700 shares. The stock had previously closed at $916.31.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q4 results and upbeat guidance reinforce growth thesis — Lilly reported robust Q4 EPS and revenue beats and reiterated elevated FY2026 EPS guidance, supporting expectations for continued GLP‑1-driven top‑line expansion. Firing on All Cylinders: Eli Lilly NYSE: LLY Q4 Earnings Lead the Way
• Positive Sentiment: Analyst upgrade nudges estimates slightly higher — Erste Group raised its FY2026 EPS forecast (small change but signal of sell‑side confidence in Lilly’s earnings trajectory).
• Positive Sentiment: Retail/pharmacy distribution expansion for Zepbound increases access — Kroger pharmacies are offering Lilly’s Zepbound with support/savings programs, which should help uptake and recurring script growth for the weight‑management franchise. What Kroger (KR)'s New Zepbound Access and Premium Ice Cream Push Means For Shareholders
• Positive Sentiment: Investor commentary and media attention remain favorable — coverage noting Lilly as a top healthcare pick and positive fund manager commentary keeps sentiment constructive for longer‑term holders. Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer?
• Neutral Sentiment: Market positioning and peer comparisons create valuation debate — articles weighing Lilly vs. Novo Nordisk and AbbVie highlight that premium valuation vs. peers drives investor rotation risk even with superior growth. Novo Nordisk Vs. Eli Lilly: Cheap Vs. Expensive, But No Clear Opportunity
• Neutral Sentiment: Ongoing public debate over GLP‑1s adds regulatory/policy uncertainty — coverage framing GLP‑1s as a societal issue can influence policy risk and public sentiment but doesn’t change near‑term revenue momentum. Eli Lilly and the ‘societal obligation’ of GLP-1s
• Negative Sentiment: Product lineup change in Europe could pressure certain revenue streams — Lilly plans to phase out select insulin products across Europe by 2027, which may disrupt sales in the near term and require channel/transition management. Eli Lilly to phase out select insulin products across Europe by 2027

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. HSBC downgraded shares of Eli Lilly and Company from a "hold" rating to a "reduce" rating and decreased their price target for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Jefferies Financial Group set a $1,300.00 price objective on Eli Lilly and Company and gave the stock a "buy" rating in a report on Friday, March 13th. BMO Capital Markets reaffirmed an "outperform" rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Sanford C. Bernstein reiterated an "outperform" rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Finally, TD Cowen increased their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a "buy" rating in a research report on Thursday, January 29th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $1,221.44.

Eli Lilly and Company Trading Down 1.9%

The company has a market capitalization of $849.09 billion, a PE ratio of 39.16, a price-to-earnings-growth ratio of 1.05 and a beta of 0.40. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The company's fifty day moving average is $1,013.13 and its 200-day moving average is $961.39.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts' consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the prior year, the business earned $5.32 earnings per share. Eli Lilly and Company's revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. purchased a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $25,000. Osbon Capital Management LLC purchased a new position in Eli Lilly and Company in the fourth quarter worth $25,000. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company in the second quarter worth $27,000. Vermillion & White Wealth Management Group LLC increased its position in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after purchasing an additional 16 shares in the last quarter. Finally, Evolution Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter worth $29,000. Institutional investors own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.